biostudies-literatureUnknown2021Karina K<h4>Introduction</h4>Elevated concentration of proinflammatory cytokines followed by hyperinflammation is one of the hallmarks of severe and critical COVID-19. In the short term, this may result in ARDS and lung injury; subsequently, this may cause pulmonary fibrosis-a disease with poor prognosis-in the long run. Among the cytokines, interleukin-1<i>β</i> (IL-1<i>β</i>) is one of the most overexpressed in COVID-19. We speculate that administration of intravenous activated autologous platelet-rich plasma (aaPRP), which contains interleukin-1 receptor antagonist (IL-1RA), would lower IL-1<i>β</i> levels and benefit the severe and critical COVID-19 patients.<h4>Methods</h4>After acquiring ethical clearance, we recruited 12 adult COVID-19 patients of both sexes from the Koja Regional Hospital Scientifica9427978https://www.ebi.ac.uk/biostudies/studies/S-EPMC8266471biostudies-literatureThe Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on "Profibrotic Cytokine" IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study.PMC8266471Fatkhurohman NAndrew HKrisandi GPuspitaningrum NZakiyah ASobariah SErnanda DNovariani RHertati YSulaeha ADRosadi IWidyastuti TKarina KChristoffel LMAfini IAini NRosliana IRosidah SfalseThe Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on "Profibrotic Cytokine" IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study.<h4>Introduction</h4>Elevated concentration of proinflammatory cytokines followed by hyperinflammation is one of the hallmarks of severe and critical COVID-19. In the short term, this may result in ARDS and lung injury; subsequently, this may cause pulmonary fibrosis-a disease with poor prognosis-in the long run. Among the cytokines, interleukin-1<i>β</i> (IL-1<i>β</i>) is one of the most overexpressed in COVID-19. We speculate that administration of intravenous activated autologous platelet-rich plasma (aaPRP), which contains interleukin-1 receptor antagonist (IL-1RA), would lower IL-1<i>β</i> levels and benefit the severe and critical COVID-19 patients.<h4>Methods</h4>After acquiring ethical clearance, we recruited 12 adult COVID-19 patients of both sexes from the Koja Regional Hospital 2021-01-01T00:00:00Z20212025-04-04T08:16:12.857Z2022-02-10T23:49:51.436ZS-EPMC82664713430679610.1155/2021/9427978